Salicylamide derivatives as nicotinic alpha 7 modulators
    2.
    发明申请
    Salicylamide derivatives as nicotinic alpha 7 modulators 有权
    水杨酰胺衍生物作为烟碱型α7调节剂

    公开(公告)号:US20100041763A1

    公开(公告)日:2010-02-18

    申请号:US12462952

    申请日:2009-08-12

    CPC分类号: C07C235/60 C07C235/62

    摘要: The application discloses compounds of Formula I: wherein Q1, Q2, R1, R2, R3, and n are defined as described herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the subject compounds.

    摘要翻译: 本申请公开了式I的化合物:其中Q1,Q2,R1,R2,R3和n如本文所述定义。 还提供了药物组合物,使用方法和制备本发明化合物的方法。

    �3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy!-pyridine,
pyrimidine and benzene derivatives as .alpha..sub.1 -adrenoceptor
antagonists
    10.
    发明授权
    �3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy!-pyridine, pyrimidine and benzene derivatives as .alpha..sub.1 -adrenoceptor antagonists 失效
    [3-(4-苯基哌嗪-1-基)丙基 - 氨基,硫代和氧基] - 吡啶,嘧啶和苯衍生物作为α1-肾上腺素受体拮抗剂

    公开(公告)号:US5688795A

    公开(公告)日:1997-11-18

    申请号:US336368

    申请日:1994-11-08

    摘要: The present invention relates to novel .alpha..sub.1 -adrenoceptor antagonists of Formula I: ##STR1## in which: p is 0 or 1; t is 0, 1 or 2; X is O, S or NR.sup.6 (in which R.sup.6 is hydro or (C.sub.1-6)alkyl); Y and Z are independently CH or N; R.sup.1 is hydro, hydroxy, halo, nitro, amino, cyano, (C.sub.1-4)alkylthio, acetylamino, trifluoroacetylamino, methylsulfonylamino, (C.sub.1-6)alkyl, (C.sub.3-6)cycloalkyl, (C.sub.3-6)cycloalkyl (C.sub.1-4)alkyl, oxazol-2-yl, aryl, heteroaryl, aryl (C.sub.1-4)alkyl, heteroaryl (C.sub.1-4)alkyl, (C.sub.1-6)alkyloxy, (C.sub.3-6)cycloalkyloxy, (C.sub.3-6)cycloalkyl (C.sub.1-4)alkyloxy, 2-propynyloxy, aryloxy, heteroaryloxy, aryl (C.sub.1-4)alkyloxy or heteroaryl (C.sub.1-4)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms and aryl or heteroaryl is optionally substituted with one to two substituents independently selected from halo and cyano); R.sup.2 is hydro, hydroxy, halo, cyano, (C.sub.1-6)alkyl or (C.sub.1-6)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms); R.sup.3 is -C (O)R.sup.7 (wherein R.sup.7 is (C.sub.1-6)alkyl, (C.sub.3-6)cycloalkyl, di(C.sub.1-4)alkylamino, N-(C.sub.1-4)alkyl-N-(C.sub.1-4)alkyloxyamino, (C.sub.1-4)alkyl((C.sub.1-4)alkyloxy)amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or piperazin-1-yl); R.sup.4 is halo, hydroxy, cyano, (C.sub.1-6)alkyl or (C.sub.1-6)alkyloxy; and R.sup.5 is (C.sub.1-6)alkyl; and the pharmaceutically acceptable salts and N-oxides thereof.

    摘要翻译: 本发明涉及式I的新型α1-肾上腺素受体拮抗剂:其中:p为0或1; t为0,1或2; X是O,S或NR6(其中R6是氢或(C1-6)烷基); Y和Z独立地为CH或N; R1为氢,羟基,卤素,硝基,氨基,氰基,(C1-4)烷硫基,乙酰氨基,三氟乙酰氨基,甲基磺酰氨基,(C1-6)烷基,(C3-6)环烷基,(C3-6)环烷基 4)烷基,恶唑-2-基,芳基,杂芳基,芳基(C 1-4)烷基,杂芳基(C 1-4)烷基,(C 1-6)烷氧基,(C 3-6)环烷氧基,(C 3-6)环烷基 (C 1-4)烷氧基,2-丙炔氧基,芳氧基,杂芳氧基,芳基(C 1-4)烷氧基或杂芳基(C 1-4)烷氧基(其中烷基任选被一至三个卤素原子取代,芳基或杂芳基任选被 一至两个独立地选自卤素和氰基的取代基); R 2是氢,羟基,卤素,氰基,(C 1-6)烷基或(C 1-6)烷氧基(其中烷基任选被一至三个卤素原子取代); R3是-C(O)R7(其中R7是(C1-6)烷基,(C3-6)环烷基,二(C1-4)烷基氨基,N-(C1-4)烷基-N-(C1-4) 烷氧基氨基,(C 1-4)烷基((C 1-4)烷氧基)氨基,吡咯烷-1-基,哌啶-1-基,吗啉-4-基或哌嗪-1-基); R4是卤素,羟基,氰基,(C1-6)烷基或(C1-6)烷氧基; 并且R 5是(C 1-6)烷基; 及其药学上可接受的盐和N-氧化物。